300-question practice set is compiled from verified student study
guides and third-party exam-preparation materials for the SEKK
Bilirubin Neonatal (BIL) external quality assessment (EQA) program.
Section 1: SEKK EQA Program & Quality Control (Questions 1–50)
Question 1: What does SEKK stand for in the context of clinical laboratory quality assessment?
A) System for External Quality Control
B) System of External Quality Assessment
C) Standardized Evaluation of Quality Control
D) System for Evaluation of Quality Compliance
Answer: B
*Rationale:* SEKK stands for System of External Quality Assessment. It is an accredited
proficiency testing provider organized by SEKK s.r.o., accredited according to ČSN EN ISO/IEC
17043.
Question 2: Which professional society provides expert oversight for the SEKK Bilirubin
Neonatal program?
A) American Academy of Pediatrics (AAP)
B) Czech Society of Clinical Biochemistry (ČSKB)
C) International Federation of Clinical Chemistry (IFCC)
D) European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
Answer: B
*Rationale:* The SEKK BIL cycles are professionally guaranteed by the Czech Society of
Clinical Biochemistry (Česká společnost klinické biochemie, ČSKB).
Question 3: What is the test ID code for the SEKK Bilirubin Neonatal program?
A) BIL
B) NEON
C) BILI
D) NEOBIL
Answer: A
*Rationale:* The SEKK program for neonatal bilirubin is identified by the code "BIL" in the SEKK
system.
Question 4: How many participants took part in the SEKK BIL2/26 cycle?
A) 86
B) 116
C) 136
D) 156
,Answer: C
*Rationale:* The BIL2/26 cycle had 136 participants, of which 18 were from Slovakia.
Question 5: In the SEKK BIL2/26 cycle, what was the overall success rate for total bilirubin?
A) 85%
B) 90%
C) 95%
D) 100%
Answer: D
*Rationale:* The BIL2/26 cycle had an excellent overall success rate of 100% for total bilirubin.
Question 6: Which manufacturer's group showed excellent reproducibility (CV = 2% for both
samples) for direct bilirubin in the BIL2/26 cycle?
A) Roche
B) Abbott
C) Siemens
D) Beckman Coulter
Answer: B
*Rationale:* The Abbott group showed excellent reproducibility for direct bilirubin in the BIL2/26
cycle, with a CV of 2% for both samples, approximately 3× better than other manufacturers.
Question 7: In the SEKK BIL1/25 cycle, which manufacturer's groups showed a positive bias of
approximately +9% for total bilirubin?
A) Roche and Abbott
B) Siemens Advia and Atellica
C) Beckman Coulter and Ortho
D) Abbott and Roche
Answer: B
*Rationale:* In the BIL1/25 cycle, the Siemens Advia and Atellica groups showed a positive bias
of approximately +9% for total bilirubin, with greater variance.
Question 8: According to SEKK long-term results, what is the approximate variability between
the most widespread analytical systems in the Czech Republic and Slovakia?
A) ±10%
B) ±15%
C) ±24%
D) ±30%
Answer: C
*Rationale:* Analysis of long-term SEKK results shows a variability of almost ±24% bias
between the most widespread analytical systems in the region.
,Question 9: How many participants in the SEKK BIL1/25 cycle reported their measurement
uncertainties?
A) 30
B) 46
C) 60
D) 80
Answer: C
*Rationale:* Sixty participants, or half of the cycle participants, reported their measurement
uncertainties.
Question 10: What was the average relative combined expanded uncertainty (U₅) for total
bilirubin in the SEKK BIL1/25 cycle?
A) 2.0%
B) 3.5%
C) 4.8%
D) 6.5%
Answer: C
*Rationale:* The average relative combined expanded uncertainty for total bilirubin was 4.8% for
both samples.
Question 11: What was the average relative combined expanded uncertainty (U₅) for direct
bilirubin in the SEKK BIL1/25 cycle?
A) 2.7%
B) 4.0%
C) 5.9%
D) 8.0%
Answer: C
*Rationale:* The average relative combined expanded uncertainty for direct bilirubin was 5.9%
for sample A and 5.9% for sample B.
Question 12: What does the Dmax range represent in SEKK EQA evaluation?
A) Maximum allowable bias
B) Maximum allowable standard deviation
C) Maximum allowable difference between participant result and target value
D) Maximum allowable uncertainty
Answer: C
*Rationale:* Dmax represents the maximum allowable difference between a participant's result
and the target value for successful performance in the EQA cycle.
, Question 13: What is the stability requirement for SEKK bilirubin samples when stored at 4–8°C
and protected from light?
A) 1 day
B) 3 days
C) 7 days
D) 14 days
Answer: B
*Rationale:* The SEKK material stability for bilirubin analysis is 3 days when stored at 4–8°C
and protected from light.
Question 14: What type of samples are used in the SEKK BIL program?
A) Fresh patient samples
B) Commercial samples
C) Lyophilized plasma
D) Whole blood
Answer: B
*Rationale:* Commercial samples are used in the SEKK BIL program.
Question 15: What tests are evaluated in the SEKK Bilirubin Neonatal program?
A) Total bilirubin only
B) Direct bilirubin only
C) Both total and direct bilirubin
D) Total, direct, and indirect bilirubin
Answer: C
*Rationale:* The SEKK BIL program evaluates both total bilirubin (Bilirubin celkový) and direct
bilirubin (Bilirubin přímý).
Question 16: In the SEKK BIL1/23 cycle, what was the overall success rate?
A) 85%
B) 90%
C) 95%
D) 99%
Answer: C
*Rationale:* The BIL1/23 cycle had an overall success rate of 95%.
Question 17: What does a positive bias indicate in SEKK EQA evaluation?
A) Participant results are lower than the target value
B) Participant results are higher than the target value
C) Participant results are exactly at the target value
D) Participant results have high precision
guides and third-party exam-preparation materials for the SEKK
Bilirubin Neonatal (BIL) external quality assessment (EQA) program.
Section 1: SEKK EQA Program & Quality Control (Questions 1–50)
Question 1: What does SEKK stand for in the context of clinical laboratory quality assessment?
A) System for External Quality Control
B) System of External Quality Assessment
C) Standardized Evaluation of Quality Control
D) System for Evaluation of Quality Compliance
Answer: B
*Rationale:* SEKK stands for System of External Quality Assessment. It is an accredited
proficiency testing provider organized by SEKK s.r.o., accredited according to ČSN EN ISO/IEC
17043.
Question 2: Which professional society provides expert oversight for the SEKK Bilirubin
Neonatal program?
A) American Academy of Pediatrics (AAP)
B) Czech Society of Clinical Biochemistry (ČSKB)
C) International Federation of Clinical Chemistry (IFCC)
D) European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
Answer: B
*Rationale:* The SEKK BIL cycles are professionally guaranteed by the Czech Society of
Clinical Biochemistry (Česká společnost klinické biochemie, ČSKB).
Question 3: What is the test ID code for the SEKK Bilirubin Neonatal program?
A) BIL
B) NEON
C) BILI
D) NEOBIL
Answer: A
*Rationale:* The SEKK program for neonatal bilirubin is identified by the code "BIL" in the SEKK
system.
Question 4: How many participants took part in the SEKK BIL2/26 cycle?
A) 86
B) 116
C) 136
D) 156
,Answer: C
*Rationale:* The BIL2/26 cycle had 136 participants, of which 18 were from Slovakia.
Question 5: In the SEKK BIL2/26 cycle, what was the overall success rate for total bilirubin?
A) 85%
B) 90%
C) 95%
D) 100%
Answer: D
*Rationale:* The BIL2/26 cycle had an excellent overall success rate of 100% for total bilirubin.
Question 6: Which manufacturer's group showed excellent reproducibility (CV = 2% for both
samples) for direct bilirubin in the BIL2/26 cycle?
A) Roche
B) Abbott
C) Siemens
D) Beckman Coulter
Answer: B
*Rationale:* The Abbott group showed excellent reproducibility for direct bilirubin in the BIL2/26
cycle, with a CV of 2% for both samples, approximately 3× better than other manufacturers.
Question 7: In the SEKK BIL1/25 cycle, which manufacturer's groups showed a positive bias of
approximately +9% for total bilirubin?
A) Roche and Abbott
B) Siemens Advia and Atellica
C) Beckman Coulter and Ortho
D) Abbott and Roche
Answer: B
*Rationale:* In the BIL1/25 cycle, the Siemens Advia and Atellica groups showed a positive bias
of approximately +9% for total bilirubin, with greater variance.
Question 8: According to SEKK long-term results, what is the approximate variability between
the most widespread analytical systems in the Czech Republic and Slovakia?
A) ±10%
B) ±15%
C) ±24%
D) ±30%
Answer: C
*Rationale:* Analysis of long-term SEKK results shows a variability of almost ±24% bias
between the most widespread analytical systems in the region.
,Question 9: How many participants in the SEKK BIL1/25 cycle reported their measurement
uncertainties?
A) 30
B) 46
C) 60
D) 80
Answer: C
*Rationale:* Sixty participants, or half of the cycle participants, reported their measurement
uncertainties.
Question 10: What was the average relative combined expanded uncertainty (U₅) for total
bilirubin in the SEKK BIL1/25 cycle?
A) 2.0%
B) 3.5%
C) 4.8%
D) 6.5%
Answer: C
*Rationale:* The average relative combined expanded uncertainty for total bilirubin was 4.8% for
both samples.
Question 11: What was the average relative combined expanded uncertainty (U₅) for direct
bilirubin in the SEKK BIL1/25 cycle?
A) 2.7%
B) 4.0%
C) 5.9%
D) 8.0%
Answer: C
*Rationale:* The average relative combined expanded uncertainty for direct bilirubin was 5.9%
for sample A and 5.9% for sample B.
Question 12: What does the Dmax range represent in SEKK EQA evaluation?
A) Maximum allowable bias
B) Maximum allowable standard deviation
C) Maximum allowable difference between participant result and target value
D) Maximum allowable uncertainty
Answer: C
*Rationale:* Dmax represents the maximum allowable difference between a participant's result
and the target value for successful performance in the EQA cycle.
, Question 13: What is the stability requirement for SEKK bilirubin samples when stored at 4–8°C
and protected from light?
A) 1 day
B) 3 days
C) 7 days
D) 14 days
Answer: B
*Rationale:* The SEKK material stability for bilirubin analysis is 3 days when stored at 4–8°C
and protected from light.
Question 14: What type of samples are used in the SEKK BIL program?
A) Fresh patient samples
B) Commercial samples
C) Lyophilized plasma
D) Whole blood
Answer: B
*Rationale:* Commercial samples are used in the SEKK BIL program.
Question 15: What tests are evaluated in the SEKK Bilirubin Neonatal program?
A) Total bilirubin only
B) Direct bilirubin only
C) Both total and direct bilirubin
D) Total, direct, and indirect bilirubin
Answer: C
*Rationale:* The SEKK BIL program evaluates both total bilirubin (Bilirubin celkový) and direct
bilirubin (Bilirubin přímý).
Question 16: In the SEKK BIL1/23 cycle, what was the overall success rate?
A) 85%
B) 90%
C) 95%
D) 99%
Answer: C
*Rationale:* The BIL1/23 cycle had an overall success rate of 95%.
Question 17: What does a positive bias indicate in SEKK EQA evaluation?
A) Participant results are lower than the target value
B) Participant results are higher than the target value
C) Participant results are exactly at the target value
D) Participant results have high precision
